PharmaTher Launches Strategic Initiative to Pursue Health Canada Approval for Generic Semaglutide in Canada, Building on FDA-Approved Ketamine Success Life Science Investing
Lexston Mining Corporation Announces Phase 1 of the Garfield Hills Work Program Life Science Investing
Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer Life Science Investing
EURneffy® 1 mg Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ?15 kg to <30 kg Life Science Investing
Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Porokeratosis Life Science Investing
OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting Life Science Investing
OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting Life Science Investing
Incyte Announces Positive CHMP Opinion for Zynyz® for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal Life Science Investing
